Cargando…

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer

BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve cancer-related outcomes in patients with BC. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aft, R L, Naughton, M, Trinkaus, K, Weilbaecher, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389411/ https://www.ncbi.nlm.nih.gov/pubmed/22617128 http://dx.doi.org/10.1038/bjc.2012.210

Ejemplares similares

Nomogram for predicting overall survival in stage II‐III colorectal cancer
por: Liu, Jungang, et al.
Publicado: (2020)

Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
por: Morris, M, et al.
Publicado: (2007)

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
por: Golan, Talia, et al.
Publicado: (2017)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences
por: D'Oronzo, Stella, et al.
Publicado: (2021)

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016)

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
por: Mochizuki, I, et al.
Publicado: (2012)

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
por: Schippinger, W, et al.
Publicado: (2007)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients
por: Li, A-Jian, et al.
Publicado: (2018)

The effect of smoking, obesity and diabetes on recurrence‐free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy
por: Croese, Alex, et al.
Publicado: (2021)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Cost-effectiveness of adjuvant chemotherapy with uracil–tegafur for curatively resected stage III rectal cancer
por: Hisashige, A, et al.
Publicado: (2008)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia
por: Oyekunle, Anthony A., et al.
Publicado: (2015)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
por: Aft, Rebecca
Publicado: (2012)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
por: Flågeng, M Hauglid, et al.
Publicado: (2009)

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer
por: Mukherjee, A, et al.
Publicado: (2010)

Elevated preoperative CEA is associated with worse survival in stage I–III rectal cancer patients
por: Tarantino, I, et al.
Publicado: (2012)

Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison
por: Soo, K-C, et al.
Publicado: (2005)

Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
por: Lu, Yani, et al.
Publicado: (2011)

Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study
por: Smith, Ashley A., et al.
Publicado: (2022)

Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol
por: Krzyzanowska, Monika K., et al.
Publicado: (2019)

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
por: Kroep, J.R., et al.
Publicado: (2015)

Presence of bone marrow micro‐metastases in stage I‐III colon cancer patients is associated with worse disease‐free and overall survival
por: Viehl, Carsten T., et al.
Publicado: (2017)

A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer
por: Barron, T I, et al.
Publicado: (2013)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer
por: Day, R S, et al.
Publicado: (2005)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
por: Schippinger, W, et al.
Publicado: (2005)

Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer
por: Nie, Ke, et al.
Publicado: (2022)

Nomogram prediction for overall survival of patients diagnosed with cervical cancer
por: Polterauer, S, et al.
Publicado: (2012)

Effects of Zoledronate on Mortality and Morbidity after Surgical Treatment of Hip Fractures
por: Cengiz, Ömer, et al.
Publicado: (2016)

Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis
por: Roka, F, et al.
Publicado: (2005)

Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer
por: Corrò, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_58ab1vegotgiga7s713jcucark